• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Tandem Diabetes Care has positive artificial pancreas data

October 25, 2023 By Sean Whooley

Tandem Diabetes Care tslim_X2_Insulin_Pump_Front_View_Control-IQ_RGB
Image from Tandem Diabetes

Data from a Tandem Diabetes Care (Nasdaq:TNDM) study demonstrated the benefits of its automated insulin delivery technology.

Diabetes Technology & Therapeutics made data available from the Control-IQ Observational (CLIO) study. It’s the largest prospective study of the Control-IQ advanced hybrid closed-loop technology to date. Twelve-month results showed, among other results, lower adverse events for type 1 diabetes patients using the technology.

Tandem Diabetes Care develops automated insulin delivery products, including its flagship t:slim X2 pump with Control-IQ technology. The company last month won FDA clearance for its Mobi automated insulin delivery system, which is less than half the size of the t:slim X2.

Control-IQ technology automatically observes and manages blood glucose levels. This artificial pancreas employs an insulin pump that uses sophisticated algorithms based on glucose monitoring data from the Dexcom G6 CGM, adjusting insulin dosage as required. The FDA has cleared Control-IQ for use in individuals aged 6 and older with type 1 diabetes.

In the study, Control-IQ led to lower observed rates for both severe hypoglycemia and diabetic ketoacidosis across all demographics. Adult participants, on average, achieved greater than 70% time in range, with pediatric participants topping 60% CGM time in range.

The study also observed a reduction in adverse events independent of baseline HbA1c, prior insulin therapy or prior CGM experience. Tandem says the lowest rate was most pronounced for people switching from multiple daily injections. It demonstrated the benefits of the technology even for those who didn’t previously consider pump therapy.

Tandem set up the study as a single-arm, prospective, longitudinal post-market surveillance. It evaluated individuals ages six and up with type 1 diabetes using Control-IQ technology in a real-world setting. In total, 2,998 subjects completed the surveillance at 12 months. All study visits took place virtually, increasing accessibility for participation to a broader range of people.

Filed Under: Clinical Trials, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Technology Tagged With: Tandem Diabetes Care

IN CASE YOU MISSED IT

  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes
  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS